43.89

0.09% 0.04

After Hours: 43.89

Xoma Royalty Corp (XOMA)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Xoma Royalty Corp stock is traded at $43.89, with a volume of 144.74K. It is up +0.09% in the last 24 hours and up +4.28% over the past month. XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.

Previous Close:

$43.85

Open:

$43.85

24h Volume:

144.74K

Relative Volume:

0.66

Market Cap:

$775.92M

Revenue:

$48.56M

Net Income/Loss:

$25.56M

P/E Ratio:

27.93

EPS:

1.5712

Net Cash Flow:

$-14.09M

1W Performance:

+3.27%

1M Performance:

+4.28%

6M Performance:

+61.30%

1Y Performance:

+67.71%

1-Day Range:

$43.58

$44.01

1-Week Range:

$42.24

$44.01

52-Week Range:

$22.29

$44.01

Xoma Royalty Corp Stock (XOMA) Company Profile

Name

Xoma Royalty Corp

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

510-204-7239

Address

2200 POWELL STREET, EMERYVILLE, CA

Employee

Twitter

@xomacorp

Next Earnings Date

2026-08-12

Latest SEC Filings

XOMA's Discussions on Twitter

Compare XOMA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XOMA Xoma Royalty Corp	43.89	775.21M	48.56M	25.56M	-14.09M	1.5712
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.93	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.50	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-25	Initiated	The Benchmark Company	Buy
Apr-29-24	Initiated	Leerink Partners	Outperform
Sep-07-21	Downgrade	Wedbush	Outperform → Neutral
Jun-29-21	Initiated	Aegis Capital	Buy
Jan-19-21	Reiterated	H.C. Wainwright	Buy
Jan-18-18	Reiterated	H.C. Wainwright	Buy
Oct-17-17	Resumed	H.C. Wainwright	Buy
Sep-05-17	Upgrade	Wedbush	Neutral → Outperform
Jun-12-17	Initiated	H.C. Wainwright	Buy
Nov-14-16	Downgrade	Wedbush	Outperform → Neutral
Mar-11-16	Reiterated	Wedbush	Outperform
Jul-23-15	Downgrade	Jefferies	Buy → Hold
Jul-22-15	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jul-22-15	Downgrade	Piper Jaffray	Overweight → Neutral
Oct-10-14	Resumed	ROTH Capital	Buy
Apr-29-14	Upgrade	MLV & Co	Hold → Buy
Mar-11-14	Downgrade	MLV & Co	Buy → Hold
Mar-05-14	Reiterated	Ladenburg Thalmann	Buy
Oct-31-13	Reiterated	MLV & Co	Buy
May-09-13	Reiterated	Ladenburg Thalmann	Buy
May-14-12	Initiated	Cowen & Co	Outperform
Mar-31-11	Reiterated	MLV Capital	Buy
Mar-23-11	Reiterated	RBC Capital Mkts	Outperform
Jan-06-11	Reiterated	Ladenburg Thalmann	Buy
Jan-04-11	Reiterated	Wedbush	Outperform

View All

Xoma Royalty Corp Stock (XOMA) Latest News

Jul 03, 2026

Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million -- WSJ - Moomoo

Jul 03, 2026

Jul 02, 2026

XOMAO Stock Price, Quote & Chart - ChartMill

Jul 02, 2026

Jun 27, 2026

XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition - Yahoo Finance

Jun 27, 2026

Jun 25, 2026

XOMA Royalty Sets July Vote on $39-per-Share Ligand Takeover and Reorganization - TipRanks

Jun 25, 2026

Jun 24, 2026